Synovial fibroblast proliferation

Synovial fibroblast proliferation refers to the pathological expansion of fibroblast-like synoviocytes (FLS) within the synovial lining of joints, a hallmark of inflammatory arthropathies like rheumatoid arthritis (RA). In a healthy joint, the synovium is a thin layer, but in RA, FLS undergo a phenotypic transformation into aggressive, 'tumor-like' cells that multiply excessively and resist apoptosis. This proliferation leads to the formation of the pannus, an invasive tissue mass that migrates onto and destroys articular cartilage and underlying bone. The process is driven by an autocrine and paracrine loop of proinflammatory cytokines, such as TNF-alpha and IL-6, as well as growth factors like PDGF. While this cellular process is a major focus of therapeutic intervention, it is considered a physiological outcome or disease manifestation rather than a specific molecular target. Current treatments, including biologics and JAK inhibitors, aim to suppress this proliferation by blocking the signaling cascades that sustain the hyperactive FLS state.

Other names

Fibroblast-like synoviocyte proliferationFLS proliferationSynovial hyperplasiaSynoviocyte hyperplasiaSynovial fibroblast expansion

Drugs do not target 'proliferation' directly as a molecule; instead, they inhibit upstream cytokines (e.g., TNF-alpha, IL-6) or intracellular signaling pathways (e.g., JAK/STAT, NF-kB) that drive the cell cycle and survival of fibroblast-like synoviocytes.